A large number of active ingredients can benefit from liposomal packaging. Many approved active ingredients cause severe side effects when used systemically because they are not targeted, or they have to be dosed too high because they only circulate in the body for a short time. A liposomal formulation opens up new possibilities here. InnoMedica's technology platform can be used both for clinically established active ingredients and for new, customized substances such as RNA or proteins. Through targeted design adjustments, InnoMedica's liposomal nanoparticle can be specifically adapted to the properties of the disease and the affected tissue, as well as the transported active ingredient. There are virtually no limits to InnoMedica's product pipeline.
In oncology, InnoMedica is currently preparing TLD-1, a refinement of the proven chemotherapy doxorubicin, for the market. InnoMedica's liposomal formulation is intended to prevent the otherwise occurring and often intolerable side effects of the well-known active ingredient. InnoMedica's neurology product TLN-1, which is currently in clinical development, is intended to counteract neurodegenerative diseases such as Parkinson's by enabling InnoMedica's transport system to cross the blood-brain barrier and thus deliver the active ingredient GM1 to the brain. InnoMedica is also developing a product to mark tumors for more precise surgical removal (TLTrace) and is working on the further development of another widely used chemotherapy docetaxel (TLTaxel).
Research
Preclinical
Clinical
The nanocarrier of InnoMedica's oncology product transports the already approved, highly effective active ingredient doxorubicin and is designed to prevent serious, sometimes irreversible side effects of this chemotherapy. The intelligent surface coating of the liposomal nanoparticle ensures minimal interaction of the active ingredient with healthy tissue. The longer blood circulation time protects the excretory organs as they have more time for the degradation process. As the liposomal nanocarrier of the preparation is particularly small, targeted penetration of the tumor tissue and thus a high level of drug accumulation in the tumor is ensured.
Thanks to the unique composition of the nanocarrier for InnoMedica's neurology product, the active ingredient GM1 ganglioside that is integrated into the membrane can cross the blood-brain barrier and unfold its neuroprotective and neuroregenerative effect in the brain. GM1 ganglioside is an important component of nerve cells and plays a central role in neuronal development, information transmission and storage, in repair mechanisms and in the release of neurotrophins (messenger substances that are essential for the survival and regeneration of nerve cells). As InnoMedica's nanocarrier crosses the blood-brain barrier, the brain is supplied with more GM1 to protect the nerve cells. As it is an endogenous substance, it is also well tolerated.
